<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00792142</url>
  </required_header>
  <id_info>
    <org_study_id>06143</org_study_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-06143</secondary_id>
    <secondary_id>MILLENNIUM-06143</secondary_id>
    <secondary_id>CDR0000624513</secondary_id>
    <nct_id>NCT00792142</nct_id>
  </id_info>
  <brief_title>Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma</brief_title>
  <official_title>A Phase II Study of Maintenance Treatment With Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking&#xD;
      blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking&#xD;
      some of the enzymes needed for cell growth. Giving bortezomib together with thalidomide and&#xD;
      dexamethasone may kill any cancer cells that remain after high-dose melphalan and stem cell&#xD;
      transplant in patients with multiple myeloma.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of giving bortezomib together with&#xD;
      thalidomide and dexamethasone after melphalan and stem cell transplant and to see how well it&#xD;
      works in treating patients with stage I-III multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the feasibility and toxicities of maintenance therapy with sequential&#xD;
           bortezomib, thalidomide, and dexamethasone after high-dose melphalan and autologous&#xD;
           peripheral blood stem cell transplantation in patients with multiple myeloma.&#xD;
&#xD;
        -  To assess whether administration of sequential bortezomib, thalidomide, and&#xD;
           dexamethasone can improve progression-free survival of these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess whether administration of sequential bortezomib, thalidomide, and&#xD;
           dexamethasone can increase complete remission rate and duration of response in these&#xD;
           patients.&#xD;
&#xD;
        -  To assess the impact of maintenance therapy with sequential bortezomib, thalidomide, and&#xD;
           dexamethasone after transplantation on overall survival of these patients.&#xD;
&#xD;
        -  To evaluate the influence of cytogenetic abnormalities (e.g., chromosome 13 deletion, 14&#xD;
           q32 abnormality, t [4;14], chromosome 1 q21 amplification, and chromosome 17 deletion)&#xD;
           on outcome by performing conventional cytogenetic study and fluorescence in situ&#xD;
           hybridization (FISH) studies on baseline and post-transplant bone marrow specimens.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  High-dose melphalan and autologous peripheral blood stem cell transplantation (PBSCT):&#xD;
           Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo&#xD;
           autologous PBSCT on day 0. Patients receive filgrastim (G-CSF) IV or subcutaneously&#xD;
           beginning on day 5 and continuing until blood counts recover.&#xD;
&#xD;
        -  Maintenance therapy: Beginning 4-8 weeks after transplantation, patients receive&#xD;
           bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the&#xD;
           absence of disease progression or unacceptable toxicity. Patients also receive oral&#xD;
           dexamethasone on days 1-4; treatment with dexamethasone repeats every month for 12&#xD;
           months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks&#xD;
           after completion of bortezomib, patients receive oral thalidomide once daily until&#xD;
           disease progression.&#xD;
&#xD;
      Patients complete the FACT-GOG neurotoxicity questionnaire periodically. Bone marrow samples&#xD;
      are collected at baseline and post-transplant for cytogenetic analysis by FISH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 16, 2008</start_date>
  <completion_date type="Actual">April 21, 2014</completion_date>
  <primary_completion_date type="Actual">April 21, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>After 4 months of maintenance therapy</time_frame>
    <description>All grade 3 and above treatment-related adverse events (AEs) during bortezomib/dexamethasone treatment cycles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>One Year Overall Survival</measure>
    <time_frame>From date of treatment initiation until death from any cause, assessed up to one year.</time_frame>
    <description>One year overall survival estimated using the product-limit method of Kaplan and Meier. Defined as the percentage of patients alive at year one after starting treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of Response in Patients Started on Maintenance Therapy</measure>
    <time_frame>Post-Thalidomide at 1 year.</time_frame>
    <description>Complete Response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow.&#xD;
Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level &lt; 100mg per 24-h.&#xD;
Partial Response (PR): &gt; 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by &gt; 90% or to &lt; 200mg per 24-h In addition to the above listed criteria, if present at baseline, a . 50% reduction in the size of soft tissue plasmacytomas is also required.&#xD;
Stable Disease (SD): Not meeting criteria for CR, VGPR, PR or progressive disease.&#xD;
Relapse: Any of the following: Reappearance of serum or urine M-protein by immunofixation or electrophoresis Development of &gt; 5% plasma cells in the bone marrow. Appearance of any other sign of progression (i.e., new plasmacytoma, lytic bone lesion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One Year Progression-free Survival (PFS)</measure>
    <time_frame>From start of treatment initiation until disease progression, relapse or death from any cause, assessed up to 1 year.</time_frame>
    <description>PFS estimated using the product-limit method of Kaplan and Meier. Defined as the percentage of patients progression-free at year one after starting treatment.&#xD;
International Myeloma Working Group uniform response criteria for disease progression:&#xD;
Increase of &gt; 25% from baseline in Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dl); Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h; Only in patients without measurable serum and urine M-protein levels:&#xD;
the difference between involved and uninvolved FLC levels. The absolute increase must be &gt;l0mg/dl.&#xD;
Bone marrow plasma cell percentage: the absolute % must be &gt; 10%C; Definite development of new bone lesions or soft tissue plasmacytomas.&#xD;
or definite increase in the size of existing bone lesions or soft tissue plasmacytomas Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dl or 2.65 mmol/l) that can be attributed solely to the plasma cell proliferative disorder.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Neurotoxicity</condition>
  <arm_group>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high-dose melphalan IV over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation on day 0. Patients receive filgrastim IV or SC beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive oral thalidomide once daily until disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>cytogenetic analysis</intervention_name>
    <description>Performed on baseline and post transplant bone marrow specimens</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
    <description>Performed on baseline and post transplant bone marrow specimens</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan</description>
    <arm_group_label>Treatment (stem cell transplant, maintenance treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multiple Myeloma patients with symptomatic disease, stage II or III at diagnosis or&#xD;
             progressive stage I requiring chemotherapy and/or radiation therapy (by Salmon-Durie&#xD;
             classification), who are not eligible for tandem transplant study using TMI; because&#xD;
             of previous radiation or eligibility criteria; documentation of disease staging by&#xD;
             both Salmon-Durie classification and International Staging System (ISS) is required&#xD;
&#xD;
          -  Patients with non-secretory myeloma should have measurable serum free-light chain&#xD;
             protein by the Free-lite test or measurable disease such as a soft tissue myeloma&#xD;
&#xD;
          -  A minimum of 4 x 10^6 of CD 34 Positive cell/kg has been harvested&#xD;
&#xD;
          -  A Karnofsky performance status (KPS) of &gt;= 70% is required unless the KPS is impaired&#xD;
             due to bone disease&#xD;
&#xD;
          -  No contraindication to the collection of a minimum of 4 x 10^6 CD34+ cells/kg by&#xD;
             apheresis&#xD;
&#xD;
          -  All patients must have signed a voluntary, informed consent in accordance with&#xD;
             institutional and federal guidelines&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 mg/dl&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate&#xD;
             transaminase (SGPT) &lt; 2.5 x upper limits of normal&#xD;
&#xD;
          -  Creatinine clearance of &gt;= 40cc/min&#xD;
&#xD;
          -  Absolute neutrophil count of &gt; 1000/ul&#xD;
&#xD;
          -  Platelet count of &gt; 100,000/ul&#xD;
&#xD;
          -  Cardiac ejection fraction &gt;= 45% by multigated acquisition (MUGA) scan and/or by&#xD;
             echocardiogram&#xD;
&#xD;
          -  Diffusing capacity of the lung for carbon monoxide (DLCO) &gt;= 50% of predicted lower&#xD;
             limit&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) antibody tests negative&#xD;
&#xD;
          -  No other medical, or psychosocial problems which in the opinion of the primary&#xD;
             physician or principal investigator would place the patient at unacceptably high risk&#xD;
             from this treatment regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of peripheral neuropathy &gt;= grade II&#xD;
&#xD;
          -  Patients with evidence of disease progression (with &gt;= 25% increase in M protein) on&#xD;
             bortezomib and or thalidomide therapy prior to transplant&#xD;
&#xD;
          -  Pregnant or nursing women, as well as women of child bearing age, who are unwilling to&#xD;
             use a dual method of contraception and men who are unwilling to use condom&#xD;
&#xD;
          -  Patients with history of hypersensitivity to bortezomib, boron or mannitol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Firoozeh Sahebi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 14, 2008</study_first_submitted>
  <study_first_submitted_qc>November 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2008</study_first_posted>
  <results_first_submitted>August 14, 2020</results_first_submitted>
  <results_first_submitted_qc>August 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurotoxicity</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 27, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT00792142/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Stem Cell Transplant, Maintenance Treatment)</title>
          <description>Patients receive high-dose melphalan IV 200mg/m^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Stem Cell Transplant, Maintenance Treatment)</title>
          <description>Patients receive high-dose melphalan IV 200mg/m^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="29" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>All grade 3 and above treatment-related adverse events (AEs) during bortezomib/dexamethasone treatment cycles.</description>
        <time_frame>After 4 months of maintenance therapy</time_frame>
        <population>Five patients did not start the maintenance phase of the study because of neurotoxicity (n=3), thrombocytopenia (n=1), or withdrawal of consent (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Stem Cell Transplant, Maintenance Treatment)</title>
            <description>Patients receive high-dose melphalan IV 200mg/m^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>All grade 3 and above treatment-related adverse events (AEs) during bortezomib/dexamethasone treatment cycles.</description>
          <population>Five patients did not start the maintenance phase of the study because of neurotoxicity (n=3), thrombocytopenia (n=1), or withdrawal of consent (n=1).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cataract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain in extremity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sinus bradycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>One Year Overall Survival</title>
        <description>One year overall survival estimated using the product-limit method of Kaplan and Meier. Defined as the percentage of patients alive at year one after starting treatment.</description>
        <time_frame>From date of treatment initiation until death from any cause, assessed up to one year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Stem Cell Transplant, Maintenance Treatment)</title>
            <description>Patients receive high-dose melphalan IV 200mg/m^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Overall Survival</title>
          <description>One year overall survival estimated using the product-limit method of Kaplan and Meier. Defined as the percentage of patients alive at year one after starting treatment.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="89" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Response in Patients Started on Maintenance Therapy</title>
        <description>Complete Response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow.&#xD;
Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level &lt; 100mg per 24-h.&#xD;
Partial Response (PR): &gt; 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by &gt; 90% or to &lt; 200mg per 24-h In addition to the above listed criteria, if present at baseline, a . 50% reduction in the size of soft tissue plasmacytomas is also required.&#xD;
Stable Disease (SD): Not meeting criteria for CR, VGPR, PR or progressive disease.&#xD;
Relapse: Any of the following: Reappearance of serum or urine M-protein by immunofixation or electrophoresis Development of &gt; 5% plasma cells in the bone marrow. Appearance of any other sign of progression (i.e., new plasmacytoma, lytic bone lesion)</description>
        <time_frame>Post-Thalidomide at 1 year.</time_frame>
        <population>Five patients did not start the maintenance phase of the study because of neurotoxicity (n=3), thrombocytopenia (n=1), or withdrawal of consent (n=1).</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Stem Cell Transplant, Maintenance Treatment)</title>
            <description>Patients receive high-dose melphalan IV 200mg/m^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Response in Patients Started on Maintenance Therapy</title>
          <description>Complete Response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow.&#xD;
Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level &lt; 100mg per 24-h.&#xD;
Partial Response (PR): &gt; 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by &gt; 90% or to &lt; 200mg per 24-h In addition to the above listed criteria, if present at baseline, a . 50% reduction in the size of soft tissue plasmacytomas is also required.&#xD;
Stable Disease (SD): Not meeting criteria for CR, VGPR, PR or progressive disease.&#xD;
Relapse: Any of the following: Reappearance of serum or urine M-protein by immunofixation or electrophoresis Development of &gt; 5% plasma cells in the bone marrow. Appearance of any other sign of progression (i.e., new plasmacytoma, lytic bone lesion)</description>
          <population>Five patients did not start the maintenance phase of the study because of neurotoxicity (n=3), thrombocytopenia (n=1), or withdrawal of consent (n=1).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>CR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>VPR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>PR</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Relapsed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Assessed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>One Year Progression-free Survival (PFS)</title>
        <description>PFS estimated using the product-limit method of Kaplan and Meier. Defined as the percentage of patients progression-free at year one after starting treatment.&#xD;
International Myeloma Working Group uniform response criteria for disease progression:&#xD;
Increase of &gt; 25% from baseline in Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dl); Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h; Only in patients without measurable serum and urine M-protein levels:&#xD;
the difference between involved and uninvolved FLC levels. The absolute increase must be &gt;l0mg/dl.&#xD;
Bone marrow plasma cell percentage: the absolute % must be &gt; 10%C; Definite development of new bone lesions or soft tissue plasmacytomas.&#xD;
or definite increase in the size of existing bone lesions or soft tissue plasmacytomas Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dl or 2.65 mmol/l) that can be attributed solely to the plasma cell proliferative disorder.</description>
        <time_frame>From start of treatment initiation until disease progression, relapse or death from any cause, assessed up to 1 year.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Stem Cell Transplant, Maintenance Treatment)</title>
            <description>Patients receive high-dose melphalan IV 200mg/m^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.</description>
          </group>
        </group_list>
        <measure>
          <title>One Year Progression-free Survival (PFS)</title>
          <description>PFS estimated using the product-limit method of Kaplan and Meier. Defined as the percentage of patients progression-free at year one after starting treatment.&#xD;
International Myeloma Working Group uniform response criteria for disease progression:&#xD;
Increase of &gt; 25% from baseline in Serum M-component and/or (the absolute increase must be &gt; 0.5 g/dl); Urine M-component and/or (the absolute increase must be &gt; 200 mg/24 h; Only in patients without measurable serum and urine M-protein levels:&#xD;
the difference between involved and uninvolved FLC levels. The absolute increase must be &gt;l0mg/dl.&#xD;
Bone marrow plasma cell percentage: the absolute % must be &gt; 10%C; Definite development of new bone lesions or soft tissue plasmacytomas.&#xD;
or definite increase in the size of existing bone lesions or soft tissue plasmacytomas Development of hypercalcemia (corrected serum calcium &gt;11.5 mg/dl or 2.65 mmol/l) that can be attributed solely to the plasma cell proliferative disorder.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="79" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over a period of 3 years and 11 months.</time_frame>
      <desc>&quot;Other Adverse Events&quot; include all events that were not severe adverse events regardless of grade or relation to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Stem Cell Transplant, Maintenance Treatment)</title>
          <description>Patients receive high-dose melphalan IV 200mg/m^2 over 30 minutes on days -2 and -1 and undergo autologous peripheral blood stem cell transplantation (Minimum dose of 2 X 10(6) CD34 + cells/kg ) on day 0. Patients receive filgrastim 5ug/kg IV or SQ beginning on day 5 and continuing until blood counts recover. Beginning 4 to 8 weeks after transplantation, patients receive maintenance therapy comprising 1.3 mg/m^2 of bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients also receive 40mg of oral dexamethasone on days 1 to 4. Treatment with dexamethasone repeats every month for 12 months in the absence of disease progression or unacceptable toxicity. Beginning 2 weeks after completion of bortezomib, patients receive 50mg/day of oral thalidomide once daily until disease progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>meddra10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>meddra10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin decreased</sub_title>
                <counts group_id="E1" events="143" subjects_affected="31" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lymphatic disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hearing loss</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dry eye syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lip pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="29" subjects_affected="15" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>General symptom</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bone infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastric infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Mucosal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Opportunistic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Peripheral nerve infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="32" subjects_affected="15" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="26" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="38" subjects_affected="19" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="41" subjects_affected="14" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Leukocyte count decreased</sub_title>
                <counts group_id="E1" events="103" subjects_affected="26" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="81" subjects_affected="22" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="64" subjects_affected="22" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="66" subjects_affected="20" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum cholesterol increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="44" subjects_affected="17" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum albumin decreased</sub_title>
                <counts group_id="E1" events="57" subjects_affected="23" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum calcium decreased</sub_title>
                <counts group_id="E1" events="36" subjects_affected="18" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum calcium increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum glucose decreased</sub_title>
                <counts group_id="E1" events="27" subjects_affected="15" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum magnesium decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum magnesium increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum phosphate decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum potassium decreased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum potassium increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum sodium decreased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum sodium increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Serum triglycerides increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="8" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Joint disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Kyphosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="20" subjects_affected="11" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Facial muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neurological disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Olfactory nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="160" subjects_affected="33" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin urine positive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Protein urine positive</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vaginal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title vocab="meddra12.0">Vaginal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hemorrhage nasal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hiccough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fat atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Rash desquamating</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Frankel, Ph.D.</name_or_title>
      <organization>City of Hope</organization>
      <phone>626-218-5265</phone>
      <email>pfrankel@coh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

